• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Deciphering chemotherapy resistance: a novel apoptosis protein profile analysis in stage II colorectal cancer.

作者信息

Li Zixiang, Fu Leilei

机构信息

Southwest Jiaotong University, Chengdu, Sichuan, China.

出版信息

BMJ Oncol. 2024 Aug 6;3(1):e000460. doi: 10.1136/bmjonc-2024-000460. eCollection 2024.

DOI:10.1136/bmjonc-2024-000460
PMID:39886117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11347687/
Abstract
摘要

相似文献

1
Deciphering chemotherapy resistance: a novel apoptosis protein profile analysis in stage II colorectal cancer.解读化疗耐药性：II期结直肠癌中一种新型凋亡蛋白谱分析
BMJ Oncol. 2024 Aug 6;3(1):e000460. doi: 10.1136/bmjonc-2024-000460. eCollection 2024.
2
Integrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with 'persister' cell profiles fail to benefit from adjuvant chemotherapy.II期结直肠癌中细胞死亡调节因子的综合多重分析表明，具有“持久”细胞特征的患者无法从辅助化疗中获益。
BMJ Oncol. 2024 Aug 6;3(1):e000362. doi: 10.1136/bmjonc-2024-000362. eCollection 2024.
3
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.基质金属蛋白酶 7 是 II 期和 III 期结直肠癌患者基于氟尿嘧啶的辅助化疗的有用标志物。
Med Oncol. 2014 Mar;31(3):824. doi: 10.1007/s12032-013-0824-0. Epub 2014 Jan 28.
4
DNA ploidy combined with tumor stroma as a biomarker for predicting the prognosis of stage II colorectal cancer patients and identifying candidates for chemotherapy.DNA倍体联合肿瘤基质作为预测II期结直肠癌患者预后及识别化疗候选者的生物标志物。
World J Surg Oncol. 2025 Feb 13;23(1):49. doi: 10.1186/s12957-025-03693-6.
5
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.鉴定甘丙肽及其受体 GalR1 作为结直肠癌化疗耐药的新型决定因素和潜在生物标志物。
Clin Cancer Res. 2012 Oct 1;18(19):5412-26. doi: 10.1158/1078-0432.CCR-12-1780. Epub 2012 Aug 2.
6
A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers.基于病理标志物的 II 期和 III 期结直肠癌患者个体化化疗的对比分析和指导。
Sci Rep. 2016 Nov 15;6:37240. doi: 10.1038/srep37240.
7
Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer.与代谢综合征相关的基因可预测 II 期结直肠癌患者的无病生存。代谢失调与结直肠癌之间的新联系。
Mol Oncol. 2014 Dec;8(8):1469-81. doi: 10.1016/j.molonc.2014.05.015. Epub 2014 Jun 10.
8
Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.在 II 期结直肠癌中使用口服替加氟/尿嘧啶（UFT）联合亚叶酸作为辅助化疗：来自台湾的倾向评分匹配研究。
BMC Cancer. 2023 Sep 25;23(1):900. doi: 10.1186/s12885-023-11310-6.
9
Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study.不同医院间辅助化疗用于 II/III 期结直肠癌患者的预后影响：一项全国性研究。
Colorectal Dis. 2018 Jul;20(7):O162-O172. doi: 10.1111/codi.14260. Epub 2018 Jun 5.
10
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.高危 II 期结直肠癌辅助化疗 3 个月与 6 个月的持续时间和效果评估：TOSCA 随机临床试验的亚组分析。
JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486.

本文引用的文献

1
Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.多区域单细胞蛋白质基因组分析 ccRCC 揭示了肿瘤内空间异质性的细胞因子驱动因素。
Cell Rep. 2022 Aug 16;40(7):111180. doi: 10.1016/j.celrep.2022.111180.
2
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.调节 T 细胞和肿瘤细胞中的 BCL-2 以增强嵌合抗原受体 T 细胞免疫疗法治疗癌症。
Cancer Discov. 2022 Oct 5;12(10):2372-2391. doi: 10.1158/2159-8290.CD-21-1026.
3
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.联合抑制 XIAP 和 BCL2 可在遗传多样性的侵袭性急性髓细胞白血病中发挥最大的治疗效果。
Nat Cancer. 2021 Mar;2(3):340-356. doi: 10.1038/s43018-021-00177-w. Epub 2021 Mar 18.
4
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.联合 venetoclax 和 8-氯腺苷靶向急性髓系白血病原始细胞的代谢脆弱性。
J Hematol Oncol. 2021 Apr 26;14(1):70. doi: 10.1186/s13045-021-01076-4.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
BCL-2 system analysis identifies high-risk colorectal cancer patients.BCL-2 系统分析鉴定出结直肠癌高危患者。
Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23.
7
Sensitization of 5-Fluorouracil-Resistant SNUC5 Colon Cancer Cells to Apoptosis by α-Mangostin.α-山竹黄酮使5-氟尿嘧啶耐药的SNUC5结肠癌细胞对凋亡敏感化
Biomol Ther (Seoul). 2016 Nov 1;24(6):604-609. doi: 10.4062/biomolther.2016.028.
8
Colorectal cancer.结直肠癌。
Nat Rev Dis Primers. 2015 Nov 5;1:15065. doi: 10.1038/nrdp.2015.65.
9
CLIC4, ERp29, and Smac/DIABLO derived from metastatic cancer stem-like cells stratify prognostic risks of colorectal cancer.CLIC4、ERp29 和源自转移性癌症干细胞样细胞的 Smac/DIABLO 可分层结直肠癌的预后风险。
Clin Cancer Res. 2014 Jul 15;20(14):3809-17. doi: 10.1158/1078-0432.CCR-13-1887. Epub 2014 Jun 10.
10
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.凋亡途径在结直肠癌中的预后价值：关于免疫组织化学鉴定的生物标志物的文献综述
Biomark Cancer. 2013 Jul 4;5:13-29. doi: 10.4137/BIC.S11475.